Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus CHILDREN S ADVIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE D SINUS COLD versus CHILDREN S ADVIL.
ALEVE-D SINUS & COLD vs CHILDREN'S ADVIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to decreased pain, inflammation, and fever through peripheral and central mechanisms.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
Ibuprofen 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
None Documented
None Documented
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
Terminal elimination half-life is 1.9–2.3 hours in children. In neonates, half-life is prolonged (up to 6 hours). Clinical context: Requires dosing every 6–8 hours for sustained antipyresis.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Renal excretion of conjugated metabolites (glucuronide and sulfate) accounts for ~90% of the administered dose. Less than 5% is excreted unchanged in urine. Biliary/fecal elimination is minor (<5%).
Category C
Category C
NSAID/Decongestant Combination
NSAID